BIRC5 and glioblastoma: The small molecule inhibitor of Survivin, YM155, substantially reduces viability of U87 and U251 human GBM cells, impairs homologous recombination, reverses epithelial to mesenchymal transition (and consequently reduces migration), reduces STAT3 activation, and potently sensitizes GBM cells to radiation [452–454].